Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Nov 24, 2023 11:54am
170 Views
Post# 35751649

Shiseido

ShiseidoCurious to know what Shiseido is planning to do now that they are not obligated to pay any royalties to Replicel when they move forward with their version of RCH-01 (hijacked from Replicel).

We can only assume their second Trial has been completed as it is now at least 3 years since it started. Were the results compelling enough to take the treatment to market ?  Then the questions is outside of Japan where (or can) they market it ?

Next question is Replicel trying to make a deal with Shiseido to sell them the marketing rights to the rest of the world or is Shiseido going to ignore Replicel and market the treatment wherever they want ?

Lastly, what is Replicel working on if they are not negotiating with Shiseido (above) :
Sell the company outright
Move forward with their own version of the hair treatment in Japan
Submit the Dermal Injector for FDA Approval
Sell the Dermal injector
Take Replicel private

I am sure there are many more options.


<< Previous
Bullboard Posts
Next >>